Gilotrif and Conjunctivitis aggravated - a phase IV clinical study of FDA data


Conjunctivitis aggravated is found among people who take Gilotrif, especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Gilotrif and have Conjunctivitis aggravated. It is created by eHealthMe based on reports of 5,920 people who have side effects when taking Gilotrif from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 21, 2023

5,920 people reported to have side effects when taking Gilotrif.
Among them, 33 people (0.56%) have Conjunctivitis aggravated.

What is Gilotrif?

Gilotrif has active ingredients of afatinib dimaleate. eHealthMe is studying from 5,929 Gilotrif users for its effectiveness, alternative drugs and more.

What is Conjunctivitis aggravated?

Conjunctivitis aggravated (worse infection of conjunctiva) is found to be associated with 1,282 drugs and 322 conditions by eHealthMe.

Number of Gilotrif and Conjunctivitis aggravated reports submitted per year:

Could Gilotrif cause Conjunctivitis aggravated?

Time on Gilotrif when people have Conjunctivitis aggravated *:

  • < 1 month: 40.0 %
  • 1 - 6 months: 53.33 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 6.67 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Conjunctivitis aggravated when taking Gilotrif *:

  • female: 68.75 %
  • male: 31.25 %

Age of people who have Conjunctivitis aggravated when taking Gilotrif *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 3.12 %
  • 50-59: 6.25 %
  • 60+: 90.62 %

Common drugs people take besides Gilotrif *:

  1. Tylenol: 1 person, 3.03%
  2. Sulfamethoxazole And Trimethoprim: 1 person, 3.03%
  3. Potassium: 1 person, 3.03%
  4. Plavix: 1 person, 3.03%
  5. Oxycodone: 1 person, 3.03%
  6. Metformin: 1 person, 3.03%
  7. Lisinopril And Hydrochlorothiazide: 1 person, 3.03%
  8. Humulin R: 1 person, 3.03%
  9. Humulin N: 1 person, 3.03%
  10. Humalog: 1 person, 3.03%

Common side effects people have besides Conjunctivitis aggravated *:

  1. Diarrhea: 16 people, 48.48%
  2. Rashes (redness): 14 people, 42.42%
  3. Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 12 people, 36.36%
  4. Malignant Neoplasm Progression (cancer tumour came back): 8 people, 24.24%
  5. Paronychia (infection in the tissues adjacent to a nail on a finger or toe): 8 people, 24.24%
  6. Stomatitis (inflammation of mucous membrane of mouth): 8 people, 24.24%
  7. Dermatitis Acneiform (dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis): 6 people, 18.18%
  8. Nausea (feeling of having an urge to vomit): 6 people, 18.18%
  9. Itching: 5 people, 15.15%
  10. Hair Loss: 5 people, 15.15%

Common conditions people have *:

  1. Lung Cancer - Non-Small Cell (lung cancer): 19 people, 57.58%
  2. Lung Adenocarcinoma (a form of non-small cell lung cancer): 8 people, 24.24%
  3. Rashes (redness): 3 people, 9.09%
  4. Oedema (fluid collection in tissue): 3 people, 9.09%
  5. Liver Disorder (liver diseases): 3 people, 9.09%
  6. Lung Neoplasm Malignant (cancer tumour of lung): 2 people, 6.06%
  7. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 6.06%
  8. Pain: 1 person, 3.03%
  9. Metastatic Pain (pain due to cancer spread): 1 person, 3.03%
  10. Lung Cancer Metastatic (lung cancer spreads to other parts): 1 person, 3.03%

* Approximation only. Some reports may have incomplete information.

Do you take Gilotrif and have Conjunctivitis aggravated?

Check whether Conjunctivitis aggravated is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Conjunctivitis aggravated and when was it recovered:

Expand to all the drugs that have ingredients of afatinib dimaleate:

Alternative drugs to, pros and cons of Gilotrif:

Common Gilotrif side effects:

Browse all side effects of Gilotrif:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Conjunctivitis aggravated treatments and more:

COVID vaccines that are related to Conjunctivitis aggravated:

Common drugs associated with Conjunctivitis aggravated:

All the drugs that are associated with Conjunctivitis aggravated:

Common conditions associated with Conjunctivitis aggravated:

All the conditions that are associated with Conjunctivitis aggravated:

How the study uses the data?

The study uses data from the FDA. It is based on afatinib dimaleate (the active ingredients of Gilotrif) and Gilotrif (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: